Terms: = Breast cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Prognosis
321 results:
1. The Effect of Salvianolic Acid A on Tumor-Associated Macrophage Polarization and Its Mechanisms in the Tumor Microenvironment of Triple-Negative breast cancer.
Tang C; Jiang ST; Li CX; Jia XF; Yang WL
Molecules; 2024 Mar; 29(7):. PubMed ID: 38611749
[TBL] [Abstract] [Full Text] [Related]
2. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.
Li Y; Yang W; Liu C; Zhou S; Liu X; Zhang T; Wu L; Li X; Zhang J; Chang E
Int Immunopharmacol; 2024 May; 132():111918. PubMed ID: 38537539
[TBL] [Abstract] [Full Text] [Related]
3. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
4. TP53
Su Y; Zhao J; Fu H; Liu Z; Du P; Zheng J; Wu J; Zhang J
Biochem Pharmacol; 2024 Mar; 221():116047. PubMed ID: 38331350
[TBL] [Abstract] [Full Text] [Related]
5. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract] [Full Text] [Related]
6. Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/erk pathway.
Li Y; Fan L; Yan A; Ren X; Zhao Y; Hua B
J Transl Med; 2024 Jan; 22(1):112. PubMed ID: 38282047
[TBL] [Abstract] [Full Text] [Related]
7. Promotion effect of FOXCUT as a microRNA sponge for miR-24-3p on progression in triple-negative breast cancer through the p38 MAPK signaling pathway.
Yu X; Qian F; Zhang X; Zhu Y; He G; Yang J; Wu X; Zhou Y; Shen L; Shi X; Zhang H; Liu X
Chin Med J (Engl); 2024 Jan; 137(1):105-114. PubMed ID: 38178324
[TBL] [Abstract] [Full Text] [Related]
8. SLC35A2 expression drives breast cancer progression via erk pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract] [Full Text] [Related]
9. Para-toluenesulfonamide, a novel potent carbonic anhydrase inhibitor, improves hypoxia-induced metastatic breast cancer cell viability and prevents resistance to αPD-1 therapy in triple-negative breast cancer.
Chen HY; Lin CE; Wu SC; Yang ZY; Chiang YF; Huang KC; Wang KL; Ali M; Shieh TM; Chang HY; Huang TC; Hsia SM
Biomed Pharmacother; 2023 Nov; 167():115533. PubMed ID: 37748406
[TBL] [Abstract] [Full Text] [Related]
10. A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells.
Kim ES; Kim S; Moon A
Oncol Res; 2023; 31(6):867-875. PubMed ID: 37744269
[TBL] [Abstract] [Full Text] [Related]
11. Nanoparticle (NP)-mediated APOC1 silencing to inhibit MAPK/erk and NF-κB pathway and suppress breast cancer growth and metastasis.
Liu S; Zhang F; Liang Y; Wu G; Liu R; Li X; Saw PE; Yang Z
Sci China Life Sci; 2023 Nov; 66(11):2451-2465. PubMed ID: 37668862
[TBL] [Abstract] [Full Text] [Related]
12. N-3, a novel synthetic derivative of bifendate, inhibits metastasis of triple-negative breast cancer via decreasing p38-regulated FOXC1 protein stability.
Wang F; Liao R; Wang X; Xiong G; Zhang B; Li J; Wu D; Chen Y; Zhou X; Gu X; Qi Q; Li C
Biochem Pharmacol; 2023 Sep; 215():115729. PubMed ID: 37558004
[TBL] [Abstract] [Full Text] [Related]
13. Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative breast cancer: Reactivation of Silenced ER-α and Signaling through ER-α36.
Al-Kabariti AY; Abbas MA
Mol Cancer Res; 2023 Nov; 21(11):1123-1138. PubMed ID: 37462782
[TBL] [Abstract] [Full Text] [Related]
14. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.
Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
[TBL] [Abstract] [Full Text] [Related]
15. A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/erk signaling.
Lyu Y; Tan B; Li L; Liang R; Lei K; Wang K; Wu D; Lin H; Wang M
Cell Death Dis; 2023 Jun; 14(6):346. PubMed ID: 37264022
[TBL] [Abstract] [Full Text] [Related]
16. cancer Cells Promote Immune Regulatory Function of Macrophages by Upregulating Scavenger Receptor MARCO Expression.
Gu C; Wiest M; Zhang W; Halder K; Zurawski S; Zurawski G; Joo H; Oh S
J Immunol; 2023 Jul; 211(1):57-70. PubMed ID: 37212598
[TBL] [Abstract] [Full Text] [Related]
17. Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
Ren Z; Xue Y; Liu L; Zhang X; Pei J; Zhang Y; Wang Y; Yu K
Cancer Lett; 2023 Jul; 565():216221. PubMed ID: 37192729
[TBL] [Abstract] [Full Text] [Related]
18. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of erk signaling for treatment of ERRα positive TNBC.
Musheyev D; Miller E; Birnbaum N; Miller E; Erblich S; Schuck A; Alayev A
PLoS One; 2023; 18(5):e0283047. PubMed ID: 37163498
[TBL] [Abstract] [Full Text] [Related]
20. Perfluoroalkyl substances promote breast cancer progression via ERα and GPER mediated PI3K/Akt and MAPK/erk signaling pathways.
Liu Q; Liu Y; Li X; Wang D; Zhang A; Pang J; He J; Chen X; Tang NJ
Ecotoxicol Environ Saf; 2023 Jun; 258():114980. PubMed ID: 37148752
[TBL] [Abstract] [Full Text] [Related]
[Next]
